• profile
  • History
  • Business Model
    • Portfolio Model
    • Licensing
  • Management Team
  • Board of Directors
  • Consultative Committee
  • Professional Affiliations

• products
  • Nimotuzumab
    • Science
    • Safety Profile
    • Clinical Trials
    • Consortium
    • Licensee Links
  • AeroLEF®
    • Science
    • Variable Dosing
    • Clinical Trials
  • CYT387
    • Science
    • Clinical Trials
  • CYT997
    • Science
    • Clinical Trials
  • Clinical Trials
  • Request Medical Info

• investors
  • Financial Reports
  • Regulatory Filings
  • Stock Information
  • Press Releases
  • Calendar of Events
  • Presentations
  • Corporate Governance
  • Investor Contacts
  • Email Sign-up
  • F.A.Q.

• patients
  • Nimotuzumab
    • Patients - Canada
    • Patients - USA
    • Patients - Worldwide
  • CYT387
  • CYT997
  • AeroLEF®

• physicians
  • Nimotuzumab
  • CYT387
  • CYT997
  • AeroLEF®

• contact
  • Investor Contacts
  • Licensing Contact
  • Clinical Contact

Licensee Links

YM BioSciences has engaged a global consortium of companies committed to the clinical development and marketing of nimotuzumab. Nimotuzumab's anti-tumor activity has led to its approval for marketing in 23 countries, and clinical research is ongoing around the world. Following is a partial list of nimotuzumab consortium members:

YM BioSciences/CIMYM BioSciences Licensees:

  Center of Molecular Immunology  (CIMAher® product website)

  Daiichi-Sankyo Co., Ltd. 

  Innogene Kalbiotech Pte., Ltd.  (a subsidiary of Kalbe Pharm Co., Ltd.)

  Kuhnil Pharmaceutical Co., Ltd.

  Oncoscience A.G.

CIMAB Licensees:

  Biocon

  Biotech Pharmaceutical Co., Ltd.

  Eurofarma

  Laboratorios PiSA

Nimotuzumab is licensed to YM's majority-owned subsidiary, CIMYM BioSciences Inc., by CIMAB S.A., and was developed at the Center of Molecular Immunology.